Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis
The US Food and Drug Administration has granted approval for Xatmep to treat pediatric patients with acute lymphoblastic leukemia and active polyarticular juvenile idiopathic arthritis. This regulatory action marks the first approval for this medication in these pediatric populations. The approval covers two distinct clinical scenarios: use as a component of a combination chemotherapy maintenance regimen and use for patients who are intolerant of or have an inadequate response to first-line therapy.
Detailed data regarding the primary outcomes, secondary outcomes, and specific adverse events were not reported in the provided documentation. Consequently, specific efficacy metrics such as response rates or hazard ratios are unavailable for this summary. The sample size and study setting were also not reported.
Safety and tolerability profiles, including rates of discontinuations and serious adverse events, were not reported in the available text. The FDA approval represents the current regulatory status for this intervention in the specified conditions.
Clinicians should note that this information is based solely on the FDA approval announcement. Further clinical trial data or post-marketing surveillance reports may provide additional context regarding efficacy and safety in the future.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Methotrexate is a folate analog metabolic inhibitor. It inhibits dihydrofolate reductase, interfering with DNA synthesis and cell replication.
Xatmep is indicated for: (1) Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen. (2) Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose NSAIDs.
Xatmep is for oral use only. Use another formulation for other routes. Measure with an accurate device (not a household teaspoon). For ALL: 20 mg/m2 once weekly. For pJIA: starting dose 10 mg/m2 once weekly; adjust gradually. Doses >20 mg/m2/week may increase toxicity; doses 20-30 mg/m2/week may be better absorbed via alternative route. Therapeutic response in pJIA usually begins within 3-6 weeks. Folate supplementation may reduce mouth sores in pJIA. Assess hematologic, hepatic, and renal function before and during therapy. Exclude pregnancy before starting.
For pJIA: A 6-month, double-blind, placebo-controlled trial in 127 pediatric patients (mean age 10.1 years, range 2.5-18) with JIA on background NSAIDs and/or prednisone. Methotrexate 10 mg/m2 weekly provided significant clinical improvement vs placebo by physician’s global assessment and a patient composite score. Over two-thirds had polyarticular-course JIA, with greatest response in this subgroup. Dose of 5 mg/m2 was not significantly better than placebo. For ALL: Trial data not available in label.
Contraindicated in pregnancy for non-malignant diseases (pJIA) and in patients with severe hypersensitivity to methotrexate. Warnings include: embryo-fetal toxicity, fatal toxicity from mistaken daily use, bone marrow suppression, hepatic and renal toxicity, and need for monitoring. Xatmep is a cytotoxic drug; follow special handling procedures.
Xatmep is a liquid methotrexate formulation for pediatric patients requiring oral therapy. For ALL, it is used as part of combination maintenance. For pJIA, it is second-line after NSAID failure. Dosing must be weekly; daily use is dangerous.
More on Acute Lymphoblastic Leukemia
View Original Abstract ↓
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
From Other Specialties
